While the COVID-19 vaccines introduced many people to RNA-based medicines, RNA oligonucleotides have already been on the market for years to treat diseases like Duchenne Muscular Dystrophy and ...

RNA drugs are the next frontier of medicine, but manufacturing them requires an expensive and labor-intensive process that limits production and produces metric tons of toxic chemical waste.

A newly developed mouse model enables real-time visualization of RNA Polymerase II (RNAP2) during DNA transcription, as ...

RNA-based therapeutics are transforming medicine, but scaling production efficiently remains a challenge, particularly the ...

Showcases Scalable, Sustainable Enzymatic RNA Synthesis Platform as well as an Independent Cost Analysis at Industry’s Leading Oligonucleotide Conference WATERTOWN, Mass.--(BUSINESS WIRE)--EnPlusOne ...

Within each cell, there is a constant struggle between life-sustaining molecules and molecules that could hasten its demise.

WATERTOWN, Mass.--(BUSINESS WIRE)--EnPlusOne Biosciences, Inc., a biotechnology company harnessing the power of enzymes to deliver better RNA at scale, revealed today that it had achieved the ...

The remarkably preserved mammoth has pushed the known limits of RNA survival, offering rare insights into the real-time ...

Inside every cell, a finely tuned metabolic network determines when to build, recycle, or stop producing essential molecules.

While the COVID-19 vaccines introduced many people to RNA-based medicines, RNA oligonucleotides have already been on the market for years to treat diseases like Duchenne Muscular Dystrophy and ...